CytomX Therapeutics (CTMX) Is Up 14.0% After Early Probody Colorectal Cancer Data Are Welcomed By Analysts – Has The Bull Case Changed? [Yahoo! Finance]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Yahoo! Finance
The interest centers on CytomX's condition-activated antibody prodrug approach, which aims to sharpen tumor targeting while potentially limiting damage to healthy tissue in hard-to-treat solid tumors. With the stock moving higher over the past week, we'll examine how promising Phase 1 colorectal cancer data shapes CytomX's investment narrative. Uncover the next big thing with financially sound penny stocks that balance risk and reward For CytomX, being a shareholder ultimately means buying into the idea that its Probody platform can translate early clinical signals into a sustainable pipeline, partnerships and, eventually, commercial products. The latest Phase 1 data for varsetatug maseatecan in metastatic colorectal cancer, and the subsequent analyst price target increases, sharpen that story by reinforcing varsetatug as the central near term catalyst, especially with a potential registrational path and combination work with bevacizumab on the horizon. At the same time, the st
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics (NASDAQ:CTMX) had its price target raised by analysts at Cantor Fitzgerald from $6.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
- CytomX Therapeutics to Present at Upcoming February Conferences [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics to Present at Upcoming February ConferencesGlobeNewswire
- CytomX Therapeutics (NASDAQ:CTMX) was given a new $10.00 price target on by analysts at Barclays PLC.MarketBeat
- Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) [Yahoo! Finance]Yahoo! Finance
CTMX
Earnings
- 11/6/25 - Miss
CTMX
Sec Filings
- 2/5/26 - Form SCHEDULE
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- CTMX's page on the SEC website